Pharmaceutical

Quotient Clinical has expanded its existing campus in Nottingham with the construction of 8,000 sf of laboratory space for pharmaceutical research, development, and analysis. Additionally, Quotient has acquired a 3,000-sf GMP manufacturing facility at the MediCity innovation hub in Nottingham. The lab provides eight production suites with integrated controls for high potency molecule containment and will begin operations in late 2015.

Frontage Labs opened a 36,000-sf clinical research center in Secaucus in July of 2015. Designed by DMR Architects, the facility provides a biomedical laboratory, 160 observation beds, exam rooms, administrative offices, dining facilities, a recreation center, and a pharmacy. The project was developed by retrofitting an existing building to meet the specifications of Frontage Labs, an early-stage drug development company based in Exton, Pa.

Bristol-Myers Squibb will begin construction in July of 2015 on a new research and development facility in Cambridge, Mass. Providing collaborative laboratories and offices for the creation of advanced biomedical and pharmaceutical products, the sustainably designed project comprises 208,000 sf of leased space in the Alexandria Center at Kendall Square development. Completion is expected in late 2017.

West Pharmaceutical Services broke ground in June of 2015 on a 95,000-sf manufacturing facility in Waterford, Ireland. Housing 150 employees, the project will act as a center of excellence for the production of West's proprietary elastomeric sheeting technologies and will support the manufacture of packaging components for insulin injector cartridges and other injectable drugs. The facility is expected to be fully operational in late 2018. West Pharmaceutical Services is headquartered in Exton, Pennsylvania.

Gilead Sciences opened a 45,000-sf pharmaceutical manufacturing laboratory in May of 2015 in Edmonton, Alberta. The facility is part of a two-building, $200 million campus expansion to support the production of Active Pharmaceutical Ingredients (APIs). The second buiding is currently under construction and will provide 139,000 sf of research and developent space when it opens in spring of 2016.

Green Cross Biotherapeutics began building a $256 million biopharmaceutical manufacturing facility in Canada in June of 2015. Located on the Montreal Technoparc's Saint-Laurent Campus, the project will support the production of intravenous immunoglobulin (IVIG) and albumin products, and will act as the company's North American headquarters. The 225,000-gsf facility is expected to be fully operational in 2019 and will accommodate 200 scientists, engineers, and support staff. Green Cross Biotherapeutics is headquartered Yongin, South Korea.

Alexion Pharmaceuticals is planning to build a $515 million biologics manufacturing facility in Dublin. The 215,000-sf building will be located on the College Park campus in Blanchardstown and completion is expected in 2019. Alexion's global supply chain headquarters will also become operational at the site by year-end 2015.

Novo Nordisk began construction in May of 2015 on a $223 million pharmaceutical manufacturing facility in Kalundborg, Denmark. The 81,000-sf project will support the production of active pharmaceutical ingredients for hemophelia treatments. The plant is expected to be fully operational by 2020.

The University of Texas at Tyler broke ground on the $26.5 million W.T. Brookshire Hall in late April of 2014. The three-story, 60,000-sf facility will house the Ben and Maytee Fisch College of Pharmacy. Designed to encourage student-faculty interaction and support innovative pedagogies, the project will provide flexible classrooms, research labs, skills training suites, offices, and study areas. Completion is expected in May of 2015.

WuXi Biologics began building a $150 million mammalian cell culture manufacturing facility in April of 2015 in Wuxi, China. Designed to utilize disposable bioreactors, the biopharmaceutical production plant will be the largest of its kind in the world and will be able to run continuous or semi-continuous manufacturing processes in addition to traditional modes. Completion is expected by January of 2017. WuXi Biologics is a wholly owned subsidiary of WuXi PharmaTech.

Pharmaceutical products manufacturer Bath ASU is expanding their existing campus in the United Kingdom with the construction of a 21,500-sf production plant in Corsham. Designed by Pegasus, the project will triple available cleanroom space and is being built by John Yerbury Property Developments using Kingspan Micro-Rib insulated metal wall panels. Completion is expected by June of 2015.

360 Pharma Group will begin construction in late spring of 2015 on a 300,000-sf headquarters and distribution facility in Mason, Ohio. Sited on a 47-acre campus, the $16 million project will provide office and warehouse space and will accommodate approximately 225 employees. Occupancy is expected in summer of 2016. 360 Pharma Group is the parent company of Masters Pharmaceutical, MHC Medical Products, and logistics firm RxTPL.

Nanotherapeutics is building the $135 million Advanced Development and Manufacturing Center in Alachua, Fla. Designed by RS&H, the 165,000-sf project will support vaccine development and production utilizing advanced biomanufacturing technologies. Ground was broken on the facility in October of 2013 and completion is expected by 2016. Nanotherapeutics is contracted to the Department of Defense to develop medical countermeasures to chemical and biological threats as well as infectious disease outbreaks.

Researchers at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) have completed a study of a therapeutic candidate for the Marburg virus in a BSL-4 research facility in Fort Belvoir, Va. The study was conducted entirely under Good Laboratory Practices (GLP) conditions, setting a precedent for GLP testing of medical products for BSL-4 pathogens. This may facilitate rapid evaluation and licensing by the Food and Drug Administration (FDA).

The 89,700-sf, seven-story expansion of the Wistar Institute increases research space from 30 to 45 labs, with new support areas, including tissue culture rooms, fume hood alcoves, equipment alcoves, and a shared cold room. Each of the five lab floors contains an open-plan research lab for four professors and their research teams of 35 to 40 to work collaboratively on cancer research, genetics, and vaccine development. Flexible, moveable lab benches will accommodate changing research needs.